Ocugenix
Pittsburgh
About Ocugenix
Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer immunotherapy drug is a medicine against drug-resistant bacteria, enabling doctors to perform a cancer-related eye treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $150.0K
- Funding stage: Seed
- Last round: Seed (Jun 2024)
- Website: ocugenix.com
- Phone: 412-600-6379
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/ocugenix-171371 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.